The expression of Midkine gene in patients with acute myeloid leukemia and its significance

Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluat...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Hammam, Amira A. [verfasserIn] El Dahshan, Dina H. [verfasserIn] Metwally, Hassan M. [verfasserIn] El Feky, Mohamed A. [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Schlagwörter:	Midkine gene Acute myeloid leukemia Gene expression

Übergeordnetes Werk:	Enthalten in: Comparative haematology international - London : Springer, 1991, 23(2013), 3 vom: 24. Jan., Seite 749-753
Übergeordnetes Werk:	volume:23 ; year:2013 ; number:3 ; day:24 ; month:01 ; pages:749-753

Links:	Volltext

DOI / URN:	10.1007/s00580-013-1680-1

Katalog-ID:	SPR007225504

Internformat


LEADER	01000caa a22002652 4500
001	SPR007225504
003	DE-627
005	20230519204820.0
007	cr uuu---uuuuu
008	201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s00580-013-1680-1 \|2 doi
035			\|a (DE-627)SPR007225504
035			\|a (SPR)s00580-013-1680-1-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q ASE
082	0	4	\|a 610 \|q ASE
100	1		\|a Hammam, Amira A. \|e verfasserin \|4 aut
245	1	4	\|a The expression of Midkine gene in patients with acute myeloid leukemia and its significance
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.
650		4	\|a Midkine gene \|7 (dpeaa)DE-He213
650		4	\|a Acute myeloid leukemia \|7 (dpeaa)DE-He213
650		4	\|a Gene expression \|7 (dpeaa)DE-He213
700	1		\|a El Dahshan, Dina H. \|e verfasserin \|4 aut
700	1		\|a Metwally, Hassan M. \|e verfasserin \|4 aut
700	1		\|a El Feky, Mohamed A. \|e verfasserin \|4 aut
773	0	8	\|i Enthalten in \|t Comparative haematology international \|d London : Springer, 1991 \|g 23(2013), 3 vom: 24. Jan., Seite 749-753 \|w (DE-627)559430590 \|w (DE-600)2413027-8 \|x 1433-2973 \|7 nnns
773	1	8	\|g volume:23 \|g year:2013 \|g number:3 \|g day:24 \|g month:01 \|g pages:749-753
856	4	0	\|u https://dx.doi.org/10.1007/s00580-013-1680-1 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_120
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_224
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_702
951			\|a AR
952			\|d 23 \|j 2013 \|e 3 \|b 24 \|c 01 \|h 749-753

Indexfelder

author_variant	a a h aa aah d d h e ddh ddhe h m m hm hmm f m a e fma fmae
matchkey_str	article:14332973:2013----::hepesoomdieeenainsihctmeodek
hierarchy_sort_str	2013
publishDate	2013
allfields	10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753
spelling	10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753
allfields_unstemmed	10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753
allfieldsGer	10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753
allfieldsSound	10.1007/s00580-013-1680-1 doi (DE-627)SPR007225504 (SPR)s00580-013-1680-1-e DE-627 ger DE-627 rakwb eng 610 ASE 610 ASE Hammam, Amira A. verfasserin aut The expression of Midkine gene in patients with acute myeloid leukemia and its significance 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment. Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213 El Dahshan, Dina H. verfasserin aut Metwally, Hassan M. verfasserin aut El Feky, Mohamed A. verfasserin aut Enthalten in Comparative haematology international London : Springer, 1991 23(2013), 3 vom: 24. Jan., Seite 749-753 (DE-627)559430590 (DE-600)2413027-8 1433-2973 nnns volume:23 year:2013 number:3 day:24 month:01 pages:749-753 https://dx.doi.org/10.1007/s00580-013-1680-1 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702 AR 23 2013 3 24 01 749-753
language	English
source	Enthalten in Comparative haematology international 23(2013), 3 vom: 24. Jan., Seite 749-753 volume:23 year:2013 number:3 day:24 month:01 pages:749-753
sourceStr	Enthalten in Comparative haematology international 23(2013), 3 vom: 24. Jan., Seite 749-753 volume:23 year:2013 number:3 day:24 month:01 pages:749-753
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Midkine gene Acute myeloid leukemia Gene expression
dewey-raw	610
isfreeaccess_bool	false
container_title	Comparative haematology international
authorswithroles_txt_mv	Hammam, Amira A. @@aut@@ El Dahshan, Dina H. @@aut@@ Metwally, Hassan M. @@aut@@ El Feky, Mohamed A. @@aut@@
publishDateDaySort_date	2013-01-24T00:00:00Z
hierarchy_top_id	559430590
dewey-sort	3610
id	SPR007225504
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007225504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-013-1680-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007225504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-013-1680-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hammam, Amira A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The expression of Midkine gene in patients with acute myeloid leukemia and its significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Midkine gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute myeloid leukemia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene expression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Dahshan, Dina H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Hassan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Feky, Mohamed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2013), 3 vom: 24. Jan., Seite 749-753</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:749-753</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-013-1680-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">01</subfield><subfield code="h">749-753</subfield></datafield></record></collection>
author	Hammam, Amira A.
spellingShingle	Hammam, Amira A. ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression The expression of Midkine gene in patients with acute myeloid leukemia and its significance
authorStr	Hammam, Amira A.
ppnlink_with_tag_str_mv	@@773@@(DE-627)559430590
format	electronic Article
dewey-ones	610 - Medicine & health
delete_txt_mv	keep
author_role	aut aut aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	1433-2973
topic_title	610 ASE The expression of Midkine gene in patients with acute myeloid leukemia and its significance Midkine gene (dpeaa)DE-He213 Acute myeloid leukemia (dpeaa)DE-He213 Gene expression (dpeaa)DE-He213
topic	ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression
topic_unstemmed	ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression
topic_browse	ddc 610 misc Midkine gene misc Acute myeloid leukemia misc Gene expression
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Comparative haematology international
hierarchy_parent_id	559430590
dewey-tens	610 - Medicine & health
hierarchy_top_title	Comparative haematology international
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)559430590 (DE-600)2413027-8
title	The expression of Midkine gene in patients with acute myeloid leukemia and its significance
ctrlnum	(DE-627)SPR007225504 (SPR)s00580-013-1680-1-e
title_full	The expression of Midkine gene in patients with acute myeloid leukemia and its significance
author_sort	Hammam, Amira A.
journal	Comparative haematology international
journalStr	Comparative haematology international
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	749
author_browse	Hammam, Amira A. El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A.
container_volume	23
class	610 ASE
format_se	Elektronische Aufsätze
author-letter	Hammam, Amira A.
doi_str_mv	10.1007/s00580-013-1680-1
dewey-full	610
author2-role	verfasserin
title_sort	expression of midkine gene in patients with acute myeloid leukemia and its significance
title_auth	The expression of Midkine gene in patients with acute myeloid leukemia and its significance
abstract	Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.
abstractGer	Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.
abstract_unstemmed	Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_120 GBV_ILN_152 GBV_ILN_161 GBV_ILN_171 GBV_ILN_187 GBV_ILN_224 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_702
container_issue	3
title_short	The expression of Midkine gene in patients with acute myeloid leukemia and its significance
url	https://dx.doi.org/10.1007/s00580-013-1680-1
remote_bool	true
author2	El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A.
author2Str	El Dahshan, Dina H. Metwally, Hassan M. El Feky, Mohamed A.
ppnlink	559430590
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s00580-013-1680-1
up_date	2024-07-04T02:29:16.782Z
_version_	1803613798958891008
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR007225504</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519204820.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00580-013-1680-1</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR007225504</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00580-013-1680-1-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">ASE</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Hammam, Amira A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The expression of Midkine gene in patients with acute myeloid leukemia and its significance</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Midkine (MK) is a heparin-binding growth factor and a product of a retinoic acid-responsive gene. Midkine is overexpressed in many carcinomas and thought to play an important role in carcinogenesis. However, no studies have been focused on the role of MK in AML. This study sought to evaluate the expression of MK among AML patients to explore possible correlation between MK expression and different clinicopathologic variables in an attempt to determine the prognostic value of MK expression. Mononuclear cells were separated from samples of 50 newly diagnosed cases of AML; 10 healthy volunteers were included in this study as control group. The reverse transcription polymerase chain reaction method was used to examine the expression of MK mRNA in mononuclear cells. Midkine gene mRNA expression rate was significantly higher in AML patients when compared to control group (p < 0.001); comparing Midkine expression in patients with different clinical and laboratory findings was of no statistical significance (p > 0.05). Moreover, Midkine expression was significantly higher in patients that did not achieve complete remission compared to those who succeeded to achieve one (p < 0.001). Midkine may play an important role in the tumorigenesis of AML, and evaluation of MK expression may prove to be useful for predicting response to treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Midkine gene</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Acute myeloid leukemia</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gene expression</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Dahshan, Dina H.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Metwally, Hassan M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">El Feky, Mohamed A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Comparative haematology international</subfield><subfield code="d">London : Springer, 1991</subfield><subfield code="g">23(2013), 3 vom: 24. Jan., Seite 749-753</subfield><subfield code="w">(DE-627)559430590</subfield><subfield code="w">(DE-600)2413027-8</subfield><subfield code="x">1433-2973</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:3</subfield><subfield code="g">day:24</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:749-753</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00580-013-1680-1</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2013</subfield><subfield code="e">3</subfield><subfield code="b">24</subfield><subfield code="c">01</subfield><subfield code="h">749-753</subfield></datafield></record></collection>
score	7.4004726

Nicht das Richtige dabei?

Schreiben Sie uns!

The expression of Midkine gene in patients with acute myeloid leukemia and its significance

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?